What is LIGAND PHARMS BETA CVR's earnings per share (EPS)?

LIGAND PHARMS BETA CVR (LGNZZ) reported diluted earnings per share of $6.13 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

LIGAND PHARMS BETA CVR (LGNZZ) Financials

LGNZZ OTC

Trailing 12 months to September 30, 2026

Revenue $253.8M +1.0% YoY

Net Income $51.5M +5.9% YoY

EPS (Diluted) $2.30 +13.3% YoY

Free Cash Flow $90.6M +194.6% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Oct 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LGNZZ SEC filings page.

LIGAND PHARMS BETA CVR (LGNZZ) reported $253.8M in revenue over the twelve months to Sep 30, 2026, up 1.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LGNZZ FY2025 2026-10-25

FY2025 shows recovered operating profitability, heavy development spending, and accounting earnings that converted into relatively little operating cash.

Revenue grew 60.4% and operating margin improved 28.8 percentage points from FY2024 to FY2025, indicating a sharp earnings recovery rather than mere top-line expansion. Yet operating cash flow fell 49.1% and represented only 39.7% of net income, so the recovery was not matched by cash realization.

The balance sheet expanded sharply: assets grew 65.7% while liabilities grew 388.1% between FY2024 and FY2025. Equity also grew 22.5%, but more slowly, so the new asset base came with greater reliance on liabilities than the prior year.

The 2025 cost structure points to development rather than physical reinvestment: R&D consumed 30.3% of revenue while capital expenditures were just 0.2%. Free cash flow was $48.9M against operating cash flow of $49.4M, showing that low capital spending preserved most operating cash even though operating cash itself lagged net income.

Financial Health Signals

Financial health score not available

LIGAND PHARMS BETA CVR does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/7

LIGAND PHARMS BETA CVR passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality Low Quality

0.40x

For every $1 of reported earnings, LIGAND PHARMS BETA CVR generates $0.40 in operating cash flow ($49.4M OCF vs $124.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

8.70x

LIGAND PHARMS BETA CVR earns $8.70 in operating income for every $1 of interest expense ($41.0M vs $4.7M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$78.7M

YoY-31.8%

QoQ+23.6%

5Y CAGR+5.7%

10Y CAGR+13.8%

LIGAND PHARMS BETA CVR generated $78.7M in revenue in Q3 2026. This represents a decrease of 31.8% from the same quarter a year earlier. Against the prior quarter it is up 23.6%.

EBITDA

-$5.4M

YoY-108.5%

QoQ-132.3%

LIGAND PHARMS BETA CVR's EBITDA was -$5.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 108.5% from the same quarter a year earlier. Against the prior quarter it is down 132.3%.

Net Income

-$28.5M

YoY-124.3%

QoQ-158.7%

LIGAND PHARMS BETA CVR reported a net loss of $28.5M in Q3 2026. This represents a decrease of 124.3% from the same quarter a year earlier. Against the prior quarter it is down 158.7%.

EPS (Diluted)

-$1.43

YoY-125.2%

QoQ-164.4%

LIGAND PHARMS BETA CVR earned -$1.43 per diluted share (EPS) in Q3 2026. This represents a decrease of 125.2% from the same quarter a year earlier. Against the prior quarter it is down 164.4%.

Cash & Balance Sheet

Free Cash Flow

-$27.7M

YoY-312.1%

QoQ-215.6%

LIGAND PHARMS BETA CVR recorded an outflow of $27.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents a decrease of 312.1% from the same quarter a year earlier. Against the prior quarter it is down 215.6%.

Cash & Debt

$56.0M

YoY-59.9%

QoQ-94.4%

5Y CAGR+19.0%

10Y CAGR-4.3%

LIGAND PHARMS BETA CVR held $56.0M in cash against $679.9M in long-term debt as of Q3 2026.

Shares Outstanding

20M

YoY+1.6%

QoQ+0.3%

LIGAND PHARMS BETA CVR had 20M shares outstanding in Q3 2026. This represents an increase of 1.6% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin

-20.0%

YoY-68.0pp

QoQ-33.5pp

LIGAND PHARMS BETA CVR's operating margin was -20.0% in Q3 2026, reflecting core business profitability. This is down 68.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 33.5 percentage points.

Net Margin

-36.2%

QoQ-112.3pp

5Y change-59.2pp

10Y change-41.0pp

LIGAND PHARMS BETA CVR's net profit margin was -36.2% in Q3 2026, showing the share of revenue converted to profit. Against the prior quarter it is down 112.3 percentage points. No change is given against Q3 2025: its reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

-3.0%

YoY-15.3pp

QoQ-8.0pp

5Y change-4.7pp

10Y change-3.3pp

LIGAND PHARMS BETA CVR's quarterly ROE was -3.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 15.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.0 percentage points.

Gross Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$2.8M

YoY-86.8%

QoQ-81.1%

5Y CAGR-17.9%

LIGAND PHARMS BETA CVR invested $2.8M in research and development in Q3 2026. This represents a decrease of 86.8% from the same quarter a year earlier. Against the prior quarter it is down 81.1%.

Share Buybacks

YoY-100.0%

LIGAND PHARMS BETA CVR repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Capital Expenditures

$142K

YoY+846.7%

QoQ+446.2%

5Y CAGR-39.6%

LIGAND PHARMS BETA CVR invested $142K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 846.7% from the same quarter a year earlier. Against the prior quarter it is up 446.2%.

LGNZZ Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LGNZZ quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$253.8M	$268.1M+60.4%	$167.1M+27.3%	$131.3M-33.1%	$196.2M-18.8%	$241.5M+47.7%	$163.6M+36.0%	$120.3M-52.2%	$251.5M+78.2%	$141.1M+29.5%	$109.0M+51.5%	$71.9M+11.4%	$64.5M+31.8%	$49.0M+56.0%	$31.4M+4.5%	$30.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6.3M+18.1%	$5.4M-3.7%	$5.6M-4.1%	$5.8M-36.4%	$9.1M+59.4%	$5.7M+59.2%	$3.6M-26.6%	$4.9M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$245.1M+80.6%	$135.7M+31.3%	$103.4M+56.4%	$66.1M+19.3%	$55.4M+28.1%	$43.2M+55.6%	$27.8M+10.6%	$25.1M
R&D Expenses	$23.1M	$81.2M+278.9%	$21.4M-12.7%	$24.5M-32.0%	$36.1M+12.4%	$32.1M-20.7%	$40.5M-27.6%	$55.9M+100.7%	$27.9M+3.6%	$26.9M+26.7%	$21.2M+92.8%	$11.0M+12.9%	$9.7M+5.1%	$9.3M-14.1%	$10.8M+4.8%	$10.3M
SG&A Expenses	$147.6M	$92.4M+17.5%	$78.7M+49.0%	$52.8M-24.7%	$70.1M+49.7%	$46.8M-22.0%	$60.0M+43.3%	$41.9M+11.0%	$37.7M+31.7%	$28.7M+3.6%	$27.7M+8.9%	$25.4M+12.5%	$22.6M+25.5%	$18.0M+14.0%	$15.8M+8.2%	$14.6M
Operating Income	$23.6M	$41.0Mn/m	-$22.6M-289.3%	$11.9M+293.2%	$3.0M-97.1%	$103.9M+176.9%	$37.5M-95.4%	$807.1M+392.9%	$163.7M+140.5%	$68.1M+55.1%	$43.9M+60.6%	$27.3M+39.2%	$19.6M+31.3%	$14.9M+7642.5%	$193Kn/m	-$878K
EBITDA	N/A	$74.8M+491.9%	$12.6M-73.9%	$48.5M-11.2%	$54.6M-64.8%	$154.9M+145.2%	$63.2M-92.3%	$825.4M+367.6%	$176.5M+123.3%	$79.0M+43.2%	$55.2M+84.2%	$30.0M+34.4%	$22.3M+26.6%	$17.6M+502.9%	$2.9M+52.7%	$1.9M
Interest Expense	$8.2M	$4.7M+55.3%	$3.0M+363.0%	$656K-63.5%	$1.8M-90.8%	$19.6M-28.4%	$27.4M-23.3%	$35.7M-26.0%	$48.3M+258.7%	$13.5M+4.8%	$12.8M	N/A	$4.9M+134.0%	$2.1M-29.0%	$2.9M+16.6%	$2.5M
Income Tax	$1.3M	$34.5M+426.8%	$6.5M-33.4%	$9.8M-76.1%	$41.2Mn/m	-$4.1Mn/m	-$5.3M-103.2%	$167.3M+457.6%	$30.0M-32.8%	$44.7M+332.6%	$10.3Mn/m	-$192.1M-46957.3%	$410K+9.6%	$374Kn/m	-$1.2Mn/m	-$13.3M
Net Income	$51.5M	$124.5Mn/m	-$4.0M-107.7%	$52.2Mn/m	-$33.4M-158.4%	$57.1Mn/m	-$3.0M-100.5%	$629.3M+339.1%	$143.3M+1041.5%	$12.6Mn/m	-$1.6M-100.7%	$229.8M+1811.4%	$12.0M+5.3%	$11.4Mn/m	-$527K-105.4%	$9.7M
EPS (Basic)	N/A	$6.44n/m	-$0.22-107.3%	$3.02n/m	-$1.98-157.6%	$3.44n/m	-$0.18-100.5%	$33.13+389.4%	$6.77+1028.3%	$0.60n/m	-$0.08-100.7%	$11.61+1867.8%	$0.59+5.4%	$0.56n/m	-$0.03-106.1%	$0.49
EPS (Diluted)	$2.30	$6.13n/m	-$0.22-107.5%	$2.94n/m	-$1.98-159.8%	$3.31n/m	-$0.18-100.6%	$31.85+434.4%	$5.96+1024.5%	$0.53n/m	-$0.08-100.7%	$10.83+1833.9%	$0.56+1.8%	$0.55n/m	-$0.03-106.1%	$0.49
Diluted Shares (Avg)	N/A	20M+11.0%	18M+3.0%	18M+5.3%	17M-2.2%	17M+2.5%	17M-14.8%	20M-17.9%	24M+2.5%	23M+12.7%	21M-1.9%	21M-1.0%	21M+3.3%	21M+4.5%	20M+0.7%	20M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$78.7M-31.8%	$63.7M+33.7%	$51.7M+14.1%	$59.7M+39.4%	$115.5M+122.8%	$47.6M+14.7%	$45.3M+46.3%	$42.8M+52.4%
R&D Expenses	$2.8M-86.8%	$14.7M+123.4%	$2.1M-95.7%	$3.5M-20.7%	$21.0M+270.4%	$6.6M+22.7%	$50.1M+738.8%	$4.4M-19.4%
SG&A Expenses	$72.6M+155.3%	$29.1M+44.4%	$20.8M+10.8%	$25.0M-2.3%	$28.4M+16.2%	$20.2M+14.5%	$18.8M+71.7%	$25.6M+60.1%
Operating Income	-$15.8M-128.5%	$8.6M+1.7%	$17.4Mn/m	$13.4Mn/m	$55.4M+1662.2%	$8.4Mn/m	-$36.2M-1312.0%	-$9.6Mn/m
EBITDA	-$5.4M-108.5%	$16.8M-0.9%	$25.6Mn/m	$21.6Mn/m	$63.7M+424.5%	$17.0Mn/m	-$27.4M-333.5%	-$1.0M-118.2%
Interest Expense	$2.9M+218.5%	$1.7M+51.6%	$1.7M+101.5%	$1.8M+101.2%	$910K+22.8%	$1.2M-9.1%	$867K+514.9%	$887K+577.1%
Income Tax	-$15.6M-165.4%	$15.8M+147.7%	-$10.9Mn/m	$12.0Mn/m	$23.9M+2764.8%	$6.4Mn/m	-$7.7M-128.3%	-$8.1Mn/m
Net Income	-$28.5M-124.3%	$48.5M+900.8%	-$13.3Mn/m	$44.8Mn/m	$117.3Mn/m	$4.8Mn/m	-$42.5M-149.3%	-$31.1M-270.9%
EPS (Basic)	-$1.43-123.9%	$2.42+868.0%	-$0.67n/m	$2.33n/m	$5.99n/m	$0.25n/m	-$2.21-145.5%	-$1.72-263.8%
EPS (Diluted)	-$1.43-125.2%	$2.22+825.0%	-$0.67n/m	$2.18n/m	$5.68n/m	$0.24n/m	-$2.21-146.5%	-$1.68-263.1%
Diluted Shares (Avg)	20M-3.2%	22M+9.6%	20M+3.6%	N/A	21M+12.0%	20M+10.5%	19M+5.9%	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

LGNZZ Balance Sheet

LGNZZ quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.6B+65.7%	$941.8M+19.6%	$787.2M+3.2%	$762.7M-41.2%	$1.3B-4.7%	$1.4B-8.9%	$1.5B+18.6%	$1.3B+87.9%	$671.0M+11.5%	$601.6M+19.6%	$503.1M+95.0%	$258.0M+146.4%	$104.7M+0.4%	$104.3M-13.5%	$120.6M
Current Assets	$832.3M+151.0%	$331.6M+39.6%	$237.4M-9.9%	$263.6M-43.3%	$464.8M-7.2%	$500.6M-55.5%	$1.1B+29.1%	$870.5M+267.3%	$237.0M+45.4%	$163.1M-24.1%	$214.7M+16.0%	$185.2M+644.2%	$24.9M+4.4%	$23.8M-26.1%	$32.2M
Cash & Equivalents	$174.9M+141.9%	$72.3M+215.0%	$23.0M-49.0%	$45.0M+130.5%	$19.5M-59.0%	$47.6M-33.4%	$71.5M-38.9%	$117.2M+468.2%	$20.6M+10.0%	$18.8M-80.8%	$97.4M-39.2%	$160.2M+1276.4%	$11.6M-6.0%	$12.4M+75.8%	$7.0M
Short-Term Investments	$558.6M+203.8%	$183.9M+24.8%	$147.4M-11.7%	$166.9M-48.1%	$321.6M-11.5%	$363.6M-63.6%	$998.3M+66.1%	$601.2M+232.1%	$181.0M+48.0%	$122.3M+19.0%	$102.8M+1341.1%	$7.1M+64.4%	$4.3Mn/m	$0-100.0%	$10.0M
Inventory	$9.1M-35.3%	$14.1M-41.1%	$24.0M+80.3%	$13.3M-51.4%	$27.3M+3.2%	$26.5M+263.0%	$7.3M+2.4%	$7.1M+62.9%	$4.4M+127.4%	$1.9M+17.8%	$1.6M+507.1%	$269K-80.7%	$1.4M-18.0%	$1.7M+30.4%	$1.3M
Accounts Receivable	$59.6M+55.3%	$38.4M+16.6%	$32.9M+8.2%	$30.4M-64.4%	$85.5M+50.3%	$56.8M+87.1%	$30.4M-45.6%	$55.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$101.5M-3.5%	$105.3M+1.8%	$103.4Mn/m	$0-100.0%	$105.7M-44.3%	$189.7M+99.2%	$95.2M+9.9%	$86.6M+0.8%	$86.0M+19.0%	$72.2M+490.0%	$12.2M0.0%	$12.2M0.0%	$12.2M0.0%	$12.2M0.0%	$12.2M
Total Liabilities	$543.4M+388.1%	$111.3M+29.0%	$86.3M-47.8%	$165.2M-65.3%	$476.4M-27.0%	$652.8M-10.3%	$727.7M+4.0%	$699.9M+177.3%	$252.4M+9.4%	$230.7M+2.0%	$226.2M-3.2%	$233.6M+324.0%	$55.1M-29.2%	$77.8M-25.3%	$104.1M
Current Liabilities	$37.4M+0.9%	$37.1M+121.1%	$16.8M-83.0%	$98.8M+137.2%	$41.7M-58.4%	$100.1M+488.8%	$17.0M-79.3%	$82.2M-65.6%	$238.9M+5.2%	$227.1M+1.9%	$222.8M+878.2%	$22.8M-21.3%	$28.9M-18.3%	$35.4M-18.8%	$43.6M
Non-Current Liabilities	$506.0M+581.7%	$74.2M+6.8%	$69.5M+4.7%	$66.4M-84.7%	$434.8M-21.3%	$552.6M-22.2%	$710.7M+15.1%	$617.6M+4473.1%	$13.5M+274.9%	$3.6M+8.2%	$3.3M-98.4%	$210.8M+705.9%	$26.2M-38.2%	$42.3M-29.9%	$60.4M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$320.7M-27.5%	$442.3M-30.8%	$639.0M+4.8%	$609.9Mn/m	$0	N/A	$0-100.0%	$195.9M	N/A	$27.5M	N/A
Total Equity	$1.0B+22.5%	$830.4M+18.5%	$700.9M+17.3%	$597.5M-27.2%	$821.2M+15.7%	$709.5M-7.5%	$767.2M+36.8%	$560.9M+40.3%	$399.8M+17.1%	$341.3M+43.8%	$237.3M+801.6%	$26.3M-47.0%	$49.6M+87.3%	$26.5M+223.6%	$8.2M
Retained Earnings	$608.1M+21.9%	$499.0M-0.8%	$503.0M+11.6%	$450.9M+0.4%	$449.1M+14.6%	$392.0M-2.0%	$400.1Mn/m	-$229.2Mn/m	-$400.9Mn/m	-$431.1Mn/m	-$429.5Mn/m	-$659.3Mn/m	-$671.3Mn/m	-$682.8Mn/m	-$682.2M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$2.2B+51.5%	$2.2B+130.4%	$1.5B+69.2%	$1.6B+65.7%	$1.5B+54.7%	$948.6M+9.5%	$905.4M-0.9%	$941.8M+19.6%
Current Assets	$608.2M-19.3%	$1.5B+312.8%	$865.4M+179.8%	$832.3M+151.0%	$753.9M+143.7%	$352.9M+13.0%	$309.3M-16.2%	$331.6M+39.6%
Cash & Equivalents	$56.0M-59.9%	$1.0B+1387.7%	$115.1M+139.8%	$174.9M+141.9%	$139.4M+119.1%	$67.7M+273.1%	$48.0M-4.2%	$72.3M+215.0%
Short-Term Investments	$391.4M-25.5%	$351.1M+97.9%	$664.3M+312.9%	$558.6M+203.8%	$525.1M+236.6%	$177.4M-15.1%	$160.9M-38.2%	$183.9M+24.8%
Inventory	$14.5M+21.9%	$10.3M-33.7%	$13.3M-9.2%	$9.1M-35.3%	$11.9M-28.9%	$15.5M-17.0%	$14.6M-31.5%	$14.1M-41.1%
Accounts Receivable	$83.2M+44.6%	$67.0M+62.3%	$53.4M+38.7%	$59.6M+55.3%	$57.6M+67.7%	$41.3M+10.2%	$38.5M+35.4%	$38.4M+16.6%
Long-Term Investments	$0n/m	N/A	$0n/m	N/A	$0n/m	N/A	$0n/m	N/A
Goodwill	$207.9M+104.7%	$101.5M0.0%	$101.5M0.0%	$101.5M-3.5%	$101.5M-3.5%	$101.5M-3.5%	$101.5M-3.5%	$105.3M+1.8%
Total Liabilities	$1.3B+142.3%	$1.2B+914.7%	$534.8M+386.6%	$543.4M+388.1%	$526.6M+363.2%	$120.1M+31.7%	$109.9M+2.4%	$111.3M+29.0%
Current Liabilities	$500.6M+1539.1%	$46.7M-27.8%	$40.7M-30.7%	$37.4M+0.9%	$30.5M+23.3%	$64.7M+248.7%	$58.7M+229.3%	$37.1M+121.1%
Non-Current Liabilities	$775.1M+56.3%	$1.2B+2017.1%	$494.1M+864.7%	$506.0M+581.7%	$496.1M+457.9%	$55.3M-23.8%	$51.2M-42.8%	$74.2M+6.8%
Long-Term Debt	$679.9M	$1.1B	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$961.8M+1.2%	$967.5M+16.9%	$997.3M+25.4%	$1.0B+22.5%	$950.2M+13.0%	$827.3M+6.7%	$795.6M-1.4%	$830.4M+18.5%
Retained Earnings	$554.8M-4.1%	$583.3M+26.4%	$594.7M+30.3%	$608.1M+21.9%	$578.2M+9.1%	$461.4M-14.1%	$456.5M-22.5%	$499.0M-0.8%

LGNZZ Cash Flow Statement

LGNZZ quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$91.0M	$49.4M-49.1%	$97.0M+95.8%	$49.6M-64.0%	$137.8M+74.9%	$78.8M+44.4%	$54.6Mn/m	-$29.3M-115.1%	$194.1M+119.1%	$88.6M+45.8%	$60.7M+45.5%	$41.7M+102.9%	$20.6M-0.6%	$20.7M+12750.9%	$161Kn/m	-$1.2M
Depreciation & Amortization	N/A	$33.8M-4.2%	$35.2M-3.5%	$36.5M-29.1%	$51.5M+0.9%	$51.1M+98.8%	$25.7M+39.9%	$18.4M+43.6%	$12.8M+16.7%	$11.0M-3.0%	$11.3M+329.8%	$2.6M-1.1%	$2.7M-0.2%	$2.7M-2.3%	$2.7M-2.3%	$2.8M
Stock-Based Compensation	N/A	$46.8M+14.0%	$41.1M+59.6%	$25.7M-57.3%	$60.3M+55.4%	$38.8M+26.2%	$30.7M+25.3%	$24.5M+17.6%	$20.8M-16.3%	$24.9M+31.9%	$18.9M+51.7%	$12.5M+10.5%	$11.3M+98.9%	$5.7M+39.3%	$4.1M+21.4%	$3.4M
Capital Expenditures	$405K	$452K-75.2%	$1.8M-48.3%	$3.5M-80.4%	$17.9M+104.6%	$8.8M+96.5%	$4.5M+74.6%	$2.6M+187.8%	$887K-58.9%	$2.2M+16.5%	$1.9M+1889.2%	$93K+1450.0%	$6K-98.4%	$377K-36.6%	$595K+662.8%	$78K
Free Cash Flow	$90.6M	$48.9M-48.6%	$95.2M+106.8%	$46.1M-61.6%	$119.9M+71.2%	$70.0M+39.7%	$50.1Mn/m	-$31.9M-116.5%	$193.2M+123.5%	$86.4M+46.8%	$58.9M+41.4%	$41.6M+102.5%	$20.6M+1.2%	$20.3Mn/m	-$434Kn/m	-$1.3M
Investing Cash Flow	-$669.3M	-$377.3Mn/m	-$143.7Mn/m	-$11.7M-107.1%	$163.6M+436.1%	$30.5M-86.8%	$231.6M-50.4%	$466.9Mn/m	-$423.3Mn/m	-$79.2Mn/m	-$134.4Mn/m	-$112.9Mn/m	-$2.0Mn/m	-$5.0M-493.8%	$1.3Mn/m	-$25.1M
Financing Cash Flow	$544.7M	$428.2M+340.8%	$97.1Mn/m	-$59.9Mn/m	-$276.0Mn/m	-$137.8Mn/m	-$310.5Mn/m	-$485.2M-247.7%	$328.6Mn/m	-$7.5Mn/m	-$5.0M-159.7%	$8.4M-93.6%	$130.0Mn/m	-$16.5M-520.3%	$3.9M-86.9%	$30.0M
Share Buybacks	N/A	$15.0Mn/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$78.0M-82.8%	$453.0M+268.7%	$122.9M+6149.6%	$2.0M-49.6%	$3.9M+697.8%	$489K-99.3%	$68.0Mn/m	$0n/m	$0-100.0%	$55K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$27.6M-310.8%	$24.0M+52.0%	$48.7Mn/m	$45.9M+61.3%	$13.1M-64.2%	$15.8M+18.7%	-$25.4M-235.8%	$28.5M+253.0%
Depreciation & Amortization	$10.3M+24.8%	$8.2M-3.6%	$8.2M-6.3%	$8.2M-4.8%	$8.3M-8.1%	$8.5M-3.7%	$8.8M+0.1%	$8.6M-3.2%
Stock-Based Compensation	N/A	N/A	$10.6M+35.2%	N/A	N/A	N/A	$7.8M+6.8%	N/A
Capital Expenditures	$142K+846.7%	$26K-87.9%	$228K+6.5%	$9K-98.7%	$15K-97.5%	$214K-47.5%	$214K+103.8%	$712K+70.7%
Free Cash Flow	-$27.7M-312.1%	$24.0M+53.9%	$48.5Mn/m	$45.9M+65.4%	$13.1M-63.6%	$15.6M+20.8%	-$25.7M-237.8%	$27.8M+263.0%
Investing Cash Flow	-$878.0Mn/m	$321.1Mn/m	-$94.3M-2027.8%	-$18.1Mn/m	-$353.4Mn/m	-$10.7Mn/m	$4.9Mn/m	-$38.6Mn/m
Financing Cash Flow	$4.1M-99.0%	$546.4M+3544.1%	-$14.1Mn/m	$8.3M-59.1%	$409.6M+643.7%	$15.0M+58.0%	-$4.7M-139.0%	$20.4M+283.6%
Share Buybacks	$0-100.0%	N/A	N/A	$0n/m	$15.0M	N/A	N/A	$0

Not reported in any period shown, so not listed: Dividends Paid.

LGNZZ Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LGNZZ quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	97.5%+1.3pp	96.2%+1.3pp	94.9%+3.0pp	91.9%+6.1pp	85.8%-2.5pp	88.3%-0.2pp	88.5%+4.9pp	83.7%
Operating Margin	15.3%+28.8pp	-13.5%-22.6pp	9.1%+7.5pp	1.6%-41.4pp	43.0%+20.1pp	22.9%	671.0%	65.1%+16.9pp	48.3%+8.0pp	40.3%+2.3pp	38.0%+7.6pp	30.4%-0.1pp	30.5%+29.9pp	0.6%+3.5pp	-2.9%
Net Margin	46.4%+48.8pp	-2.4%-42.1pp	39.7%+56.7pp	-17.0%-40.7pp	23.7%+25.5pp	-1.8%	523.2%	57.0%+48.1pp	8.9%+10.4pp	-1.5%	319.6%	18.6%-4.7pp	23.3%+25.0pp	-1.7%-34.0pp	32.3%
Return on Equity	12.2%+12.7pp	-0.5%-7.9pp	7.4%+13.0pp	-5.6%-12.5pp	7.0%+7.4pp	-0.4%-82.4pp	82.0%+56.5pp	25.6%+22.4pp	3.1%+3.6pp	-0.5%-97.3pp	96.9%+51.2pp	45.7%+22.7pp	23.0%+25.0pp	-2.0%-120.7pp	118.7%
Return on Assets	8.0%+8.4pp	-0.4%-7.1pp	6.6%+11.0pp	-4.4%-8.8pp	4.4%+4.6pp	-0.2%-42.3pp	42.1%+30.7pp	11.4%+9.5pp	1.9%+2.1pp	-0.3%-46.0pp	45.7%+41.0pp	4.7%-6.3pp	10.9%+11.4pp	-0.5%-8.6pp	8.1%
Current Ratio	22.23+13.3x	8.93-5.2x	14.15+11.5x	2.67-8.5x	11.15+6.2x	5.00-61.1x	66.09+55.5x	10.58+9.6x	0.99+0.3x	0.72-0.2x	0.96-7.2x	8.13+7.3x	0.86+0.2x	0.67-0.1x	0.74
Debt-to-Equity	N/A	N/A	N/A	0.00-0.4x	0.39-0.2x	0.62-0.2x	0.83-0.3x	1.09+1.1x	0.00	N/A	0.00-7.4x	7.44	N/A	1.04	N/A
Liabilities-to-Equity	0.53+0.4x	0.130.0x	0.12-0.2x	0.28-0.3x	0.58-0.3x	0.920.0x	0.95-0.3x	1.25+0.6x	0.630.0x	0.68-0.3x	0.95-7.9x	8.88+7.8x	1.11-1.8x	2.94-9.8x	12.71
Asset Turnover	0.170.0x	0.180.0x	0.17-0.1x	0.26+0.1x	0.19+0.1x	0.120.0x	0.08-0.1x	0.200.0x	0.210.0x	0.180.0x	0.14-0.1x	0.25-0.2x	0.47+0.2x	0.30+0.1x	0.25
FCF Margin	18.2%-38.7pp	57.0%+21.9pp	35.1%-26.0pp	61.1%+32.1pp	29.0%-1.7pp	30.6%+57.2pp	-26.5%-103.3pp	76.8%+15.6pp	61.2%+7.2pp	54.0%-3.9pp	57.9%+26.0pp	31.9%-9.6pp	41.5%+42.9pp	-1.4%+2.8pp	-4.2%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Margin	-20.0%-68.0pp	13.5%-4.2pp	33.6%+113.5pp	22.4%+45.0pp	48.0%+41.9pp	17.7%+63.7pp	-79.9%-89.5pp	-22.5%-10.6pp
Net Margin	-36.2%	76.2%+66.0pp	-25.8%+67.8pp	75.1%+147.7pp	101.6%	10.2%	-93.6%	-72.6%-137.3pp
Return on Equity	-3.0%-15.3pp	5.0%+4.4pp	-1.3%+4.0pp	4.4%+8.1pp	12.3%+13.2pp	0.6%+7.3pp	-5.3%-16.0pp	-3.7%-6.3pp
Return on Assets	-1.3%-9.2pp	2.2%+1.7pp	-0.9%+3.8pp	2.9%+6.2pp	7.9%+8.7pp	0.5%+6.5pp	-4.7%-14.1pp	-3.3%-5.6pp
Current Ratio	1.22-23.5x	31.18+25.7x	21.28+16.0x	22.23+13.3x	24.69+12.2x	5.45-11.4x	5.27-15.4x	8.93-5.2x
Debt-to-Equity	0.71	1.16	N/A	N/A	N/A	N/A	N/A	N/A
Liabilities-to-Equity	1.33+0.8x	1.26+1.1x	0.54+0.4x	0.53+0.4x	0.55+0.4x	0.150.0x	0.140.0x	0.130.0x
Asset Turnover	0.040.0x	0.030.0x	0.030.0x	0.040.0x	0.080.0x	0.050.0x	0.050.0x	0.050.0x
FCF Margin	-35.2%-46.5pp	37.7%+4.9pp	93.7%+150.3pp	76.9%+12.1pp	11.3%-58.0pp	32.7%+1.6pp	-56.6%-116.7pp	64.8%+37.6pp

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Where LIGAND PHARMS BETA CVR Ranks

Frequently Asked Questions

What is LIGAND PHARMS BETA CVR's annual revenue?

LIGAND PHARMS BETA CVR (LGNZZ) reported $268.1M in total revenue for fiscal year 2025. This represents a 60.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is LIGAND PHARMS BETA CVR's revenue growing?

LIGAND PHARMS BETA CVR (LGNZZ) revenue grew by 60.4% year-over-year, from $167.1M to $268.1M in fiscal year 2025.

Is LIGAND PHARMS BETA CVR profitable?

Yes, LIGAND PHARMS BETA CVR (LGNZZ) reported a net income of $51.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $124.5M, with a net profit margin of 46.4%.

What is LIGAND PHARMS BETA CVR's EBITDA?

LIGAND PHARMS BETA CVR (LGNZZ) had EBITDA of $74.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is LIGAND PHARMS BETA CVR's operating margin?

LIGAND PHARMS BETA CVR (LGNZZ) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is LIGAND PHARMS BETA CVR's net profit margin?

LIGAND PHARMS BETA CVR (LGNZZ) had a net profit margin of 46.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is LIGAND PHARMS BETA CVR's return on equity (ROE)?

LIGAND PHARMS BETA CVR (LGNZZ) has a return on equity of 12.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is LIGAND PHARMS BETA CVR's free cash flow?

LIGAND PHARMS BETA CVR (LGNZZ) generated $48.9M in free cash flow during fiscal year 2025. This represents a -48.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is LIGAND PHARMS BETA CVR's operating cash flow?

LIGAND PHARMS BETA CVR (LGNZZ) generated $49.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are LIGAND PHARMS BETA CVR's total assets?

LIGAND PHARMS BETA CVR (LGNZZ) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are LIGAND PHARMS BETA CVR's capital expenditures?

LIGAND PHARMS BETA CVR (LGNZZ) invested $452K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does LIGAND PHARMS BETA CVR spend on research and development?

LIGAND PHARMS BETA CVR (LGNZZ) invested $81.2M in research and development during fiscal year 2025.

Does LIGAND PHARMS BETA CVR buy back shares?

Yes, LIGAND PHARMS BETA CVR (LGNZZ) spent $15.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does LIGAND PHARMS BETA CVR have outstanding?

LIGAND PHARMS BETA CVR (LGNZZ) had 20M shares outstanding as of fiscal year 2025.

What is LIGAND PHARMS BETA CVR's current ratio?

LIGAND PHARMS BETA CVR (LGNZZ) had a current ratio of 22.23 as of fiscal year 2025, which is generally considered healthy.

What is LIGAND PHARMS BETA CVR's liabilities-to-equity ratio?

LIGAND PHARMS BETA CVR (LGNZZ) had a liabilities-to-equity ratio of 0.53 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is LIGAND PHARMS BETA CVR's return on assets (ROA)?

LIGAND PHARMS BETA CVR (LGNZZ) had a return on assets of 8.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is LIGAND PHARMS BETA CVR's Piotroski F-Score?

LIGAND PHARMS BETA CVR (LGNZZ) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are LIGAND PHARMS BETA CVR's earnings high quality?

LIGAND PHARMS BETA CVR (LGNZZ) has an earnings quality ratio of 0.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can LIGAND PHARMS BETA CVR cover its interest payments?

LIGAND PHARMS BETA CVR (LGNZZ) has an interest coverage ratio of 8.70x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.